Login

Tag: OOD

OOD

Regulatory/FDA

FDA Establishes Office of Oncologic Diseases to Streamline Drug Review Process

FDA Establishes Office of Oncologic Diseases to Streamline Drug Review Process

Nov. 8, 2019 – The FDA announced this week that it has reorganized its office that reviews applications for new and existing cancer therapies; its Office of Hematology Oncology Products has been renamed the Office of Oncologic Diseases (OOD) and has six divisions to accommodate a more streamlined drug review process, according to a Nov. […]

Read more

Categories

Recent Posts

Tags

ACA ad tax CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy data privacy legislation DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media FTC gifts to physicians HHS Jim Potter John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines